These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30365048)

  • 21. A detailed cell-free transcription-translation-based assay to decipher CRISPR protospacer-adjacent motifs.
    Maxwell CS; Jacobsen T; Marshall R; Noireaux V; Beisel CL
    Methods; 2018 Jul; 143():48-57. PubMed ID: 29486239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DeepCRISPR: optimized CRISPR guide RNA design by deep learning.
    Chuai G; Ma H; Yan J; Chen M; Hong N; Xue D; Zhou C; Zhu C; Chen K; Duan B; Gu F; Qu S; Huang D; Wei J; Liu Q
    Genome Biol; 2018 Jun; 19(1):80. PubMed ID: 29945655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Shooting the messenger: RNA-targetting CRISPR-Cas systems.
    Zhu Y; Klompe SE; Vlot M; van der Oost J; Staals RHJ
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29748239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRISPR-P 2.0: An Improved CRISPR-Cas9 Tool for Genome Editing in Plants.
    Liu H; Ding Y; Zhou Y; Jin W; Xie K; Chen LL
    Mol Plant; 2017 Mar; 10(3):530-532. PubMed ID: 28089950
    [No Abstract]   [Full Text] [Related]  

  • 25. The CpG island in the murine foxl2 proximal promoter is differentially methylated in primary and immortalized cells.
    Tran S; Wang Y; Lamba P; Zhou X; Boehm U; Bernard DJ
    PLoS One; 2013; 8(10):e76642. PubMed ID: 24098544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing Heritable Mutations in Arabidopsis thaliana Using a Modified CRISPR/Cas9 Toolkit Comprising PAM-Altered Cas9 Variants and gRNAs.
    Yamamoto A; Ishida T; Yoshimura M; Kimura Y; Sawa S
    Plant Cell Physiol; 2019 Oct; 60(10):2255-2262. PubMed ID: 31198958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The transcriptional targets of mutant FOXL2 in granulosa cell tumours.
    Rosario R; Araki H; Print CG; Shelling AN
    PLoS One; 2012; 7(9):e46270. PubMed ID: 23029457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disabling Cas9 by an anti-CRISPR DNA mimic.
    Shin J; Jiang F; Liu JJ; Bray NL; Rauch BJ; Baik SH; Nogales E; Bondy-Denomy J; Corn JE; Doudna JA
    Sci Adv; 2017 Jul; 3(7):e1701620. PubMed ID: 28706995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of long non-coding RNA UCA1 by CRISPR/Cas9 attenuated malignant phenotypes of bladder cancer.
    Zhen S; Hua L; Liu YH; Sun XM; Jiang MM; Chen W; Zhao L; Li X
    Oncotarget; 2017 Feb; 8(6):9634-9646. PubMed ID: 28038452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant and constitutive expression of FOXL2 impairs ovarian development and functions in mice.
    Nicol B; Rodriguez K; Yao HH
    Biol Reprod; 2020 Oct; 103(5):966-977. PubMed ID: 32945847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New vectors for simple and streamlined CRISPR-Cas9 genome editing in Saccharomyces cerevisiae.
    Laughery MF; Hunter T; Brown A; Hoopes J; Ostbye T; Shumaker T; Wyrick JJ
    Yeast; 2015 Dec; 32(12):711-20. PubMed ID: 26305040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sumoylation of forkhead L2 by Ubc9 is required for its activity as a transcriptional repressor of the Steroidogenic Acute Regulatory gene.
    Kuo FT; Bentsi-Barnes IK; Barlow GM; Bae J; Pisarska MD
    Cell Signal; 2009 Dec; 21(12):1935-44. PubMed ID: 19744555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR: development of a technology and its applications.
    Derry WB
    FEBS J; 2021 Jan; 288(2):358-359. PubMed ID: 33300275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
    Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
    Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
    Vermersch E; Jouve C; Hulot JS
    Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient and allele-specific genome editing of disease loci in human iPSCs.
    Smith C; Abalde-Atristain L; He C; Brodsky BR; Braunstein EM; Chaudhari P; Jang YY; Cheng L; Ye Z
    Mol Ther; 2015 Mar; 23(3):570-7. PubMed ID: 25418680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR-Cas systems: ushering in the new genome editing era.
    Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
    Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic exploration of the targets of FOXL2 and ESR2 unveils their implication in cell migration, invasion, and adhesion.
    Herman L; Legois B; Todeschini AL; Veitia RA
    FASEB J; 2021 Apr; 35(4):e21355. PubMed ID: 33749886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOXL2 suppresses proliferation, invasion and promotes apoptosis of cervical cancer cells.
    Liu XL; Meng YH; Wang JL; Yang BB; Zhang F; Tang SJ
    Int J Clin Exp Pathol; 2014; 7(4):1534-43. PubMed ID: 24817949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative analysis of mouse and human preimplantation development following POU5F1 CRISPR/Cas9 targeting reveals interspecies differences.
    Stamatiadis P; Boel A; Cosemans G; Popovic M; Bekaert B; Guggilla R; Tang M; De Sutter P; Van Nieuwerburgh F; Menten B; Stoop D; Chuva de Sousa Lopes SM; Coucke P; Heindryckx B
    Hum Reprod; 2021 Apr; 36(5):1242-1252. PubMed ID: 33609360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.